... parameters of gait in Parkinson s disease. HumanMovement Science, 18: 461 483.Movement Disorder Society Task Force on Rating Scales for Parkinson s Disease. (2003).The Unified Parkinson s Disease Rating ... diagnosing Parkinson s disease. Annals of Neurology, 32: S125 S127.Canning, C. G. (2005) The effect of directing attention during walking under dual taskconditions in Parkinson s disease. Parkinsonism ... of falls in Parkinson s disease. Journal of Neurology, 248:950 958.Bloem, B. R., van Vugt, J. P. P., & Beckley, D. J. (2001). Postural instability and falls in Parkinson s disease. Advance...
... University, Japan Vitamin K is a generic term for compounds thatinclude phytonadione (vitamin K1), the menaquinoneseries (vitamin K2) and menadione (vitamin K3). These vitamin K compounds ... myelodysplasticsyndrome with menatetrenone, a vitaminK2 analog.Int J Hematol 69, 24–26.13 Fujita H, Tomiyama J & Tanaka T (1998) Vitamin K2 combined with all-trans retinoic acid induced ... Viability (%) Vitamin K2 (MK-4)0********52.51.250.630.3130.15 Vitamin K10 10 (x10-7M) 10 (x10-7M)52.51.250.630.3130.15Fig. 1. Inhibition of synovial cell viability by vitamin K2(MK-4)....
... risk of aging, chronic disease, or cancer chemopre-vention and treatment in the general population.11.3 Parkinson s Disease Parkinson s disease (also known as Parkinsondisease or PD) is a degenerative ... stress, andprogression of neurodegenerative conditions such as Parkinson s and Alzheimer’sdiseases (Rahman et al., 2008).11.4 Heart Disease 11.4.1 Case Study with Digitoxin from Digitalis purpureaL. ... of the central nervous system that often impairs the sufferer’s motor skillsand speech. Parkinson s disease belongs to a group of conditions called movementdisorders. It is characterized by...
... bệnh tim mạch, tiểu đường típ 2. hội chứng liệt rung (Parkinson) . Vitamin D được gọi là nguồn vitamin trời cho. Sau gần 30 năm theo dõi sức khỏe của hơn 3.000 ... thư, hàm lượng vitamin D cao nhất có nguy cơ phát bệnh thấp hơn 67% so với những người có hàm lượng sinh tố này thấp nhất. Mặc dù chưa thể giải thích được vì sao hàm lượng vitamin D tác ... cường khả năng dẫn truyền tín hiệu điện não qua các tế bào thần kinh”. Cơ thể người tổng hợp vitamin D chủ yếu qua tiếp xúc với ánh nắng và một số loại thực phẩm như cá hồi, cá ngừ đóng...
... neuron-specific protein PGP22 PARKINSON S DISEASE AND PARKINSONISM unclear if the PD-related mutation alters this function ofthe protein (Liu et al., 2002).LRRK2LRRK2 mutations are now thought ... activator10 PARKINSON S DISEASE AND PARKINSONISM Elbaz, A., Nelson, L.M., Payami, H. et al. (2006) Lack of replica-tion of thirteen single-nucleotide polymorphisms implicated in Parkinson s disease: ... of the disease from paralysis agitans (Latin forshaking palsy) to la maladie de Parkinson (French for Parkinson s disease) . T-sub-type PD patients have a betterprognosis and slower disease...
... daytime sleepinessin Parkinson disease: an overview 349Arnulf, I.: Sleep and wakefulness disturbances in Parkinson s disease 3577. NeuroinflammationBurn, D. J.: Parkinson s disease dementia: what’s ... Parkinson s disease 305Wolters, E. Ch., Braak, H.: Parkinson s disease: premotorclinico-pathological correlations 309Berendse, H. W., Ponsen, M. M.: Detection of preclinical Parkinson s disease along ... modelof Parkinsonism – the five years inspection 269Schmidt, W. J., Alam, M.: Controversies on new animal modelsof Parkinson s disease Pro and Con: the rotenone modelof Parkinson s disease...
... MF (2007) Parkinson s disease. Hum Mol Genet 16 Spec. No. 2, R183–R194.2 Devine MJ & Lewis PA (2008) Emerging pathways ingenetic Parkinson s disease: tangles, Lewy bodies andLRRK2. FEBS ... Mitochondrial biologyand oxidative stress in Parkinsondisease pathogenesis.Nat Clin Pract Neurol 4, 600–609.6 Lesage S & Brice A (2009) Parkinson s disease: frommonogenic forms to genetic ... Theproteomic approach in Parkinson s disease. ProteomicsClin Appl 1, 1428–1435.12 Fasano M, Alberio T & Lopiano L (2008) Peripheralbiomarkers of Parkinson s disease as early reporters...
... pathway.AbbreviationsAR-JP, autosomal-recessive juvenile-onset Parkinson s disease; HtrA2, HtrA serine peptidase 2; LRRK2, leucine-rich repeat kinase 2; PD, Parkinson s disease; PINK1, PTEN-induced putative kinase ... early-onset Parkinson s disease and mutations in the Parkin gene.N Engl J Med 342, 1560–1567.3 Schapira AH (2008) Mitochondria in the aetiology andpathogenesis of Parkinson s disease. Lancet ... the molecular causes of Parkinson s disease. Trends Mol Med 12, 521–528.11 Doson MW & Guo M (2007) Pink1, Parkin, DJ-1 andmitochondrial dysfunction in Parkinson s disease. CurrOpin Neurobiol...
... Institute and Department of Neurodegenerative Disease, Institute of Neurology, London, UK Parkinson s disease (PD) is a common neurodegenera-tive disease which affects over 1% of people over ... of LRRK2-associated Parkinson s disease incentral Norway. Ann Neurol 57, 762–765.55 Funayama M, Hasegawa K, Ohta E, Kawashima N,Komiyama M, Kowa H, Tsuji S & Obata F (2005) AnLRRK2 mutation ... Genetics of Parkinson s disease: para-digm shifts and future prospects. Nat Rev Genet 7, 306–318.2 Hardy J, Cai H, Cookson MR, Gwinn-Hardy K &Singleton A (2006) Genetics of Parkinson s disease...
... Is Parkinson s Disease? 32. Who Gets Parkinson s Disease? 25PART II Signs and Symptoms of Parkinson s Disease 3. Early Symptoms 434. Moderate Parkinson s Disease 595. Advanced Parkinson s Disease ... INTRODUCTIONTable 1.2Diseases That Can Be Mistaken for Parkinson s Disease Image not available. CHAPTER2Who Gets Parkinsons Disease? ã How common is Parkinsons disease? ã Is Parkinsons related ... carbon monoxide, have beenshown to cause parkinsonism, but not, according to re-search so far, Parkinson s disease. Although the symptoms of Parkinson s disease havedistinctive, easily recognized...
... akathisia.Akathisia also commonly occurs in parkinsonian syndromes, including idiopathic Parkinson s disease. In contrast to persons with neuroleptic-related akathisia, however,parkinsonian patients typically ... example, in patients with atypical parkinsonism (so-called parkinsonismplus syndrome), the clinical diagnosis is based on the additional systems involved.If signs of parkinsonism are accompanied ... weakness dystonia and parkinsonian syndromesParaspinal weakness of • Compare with the stooped posture oftrunk,with stooping parkinsonismDysphagia • May also occur in parkinsonism,spinocerebellar...
... Smith3Surgical Treatment of Parkinson s Disease: Past, Present, and Future 41William C. Koller, Alireza Minagar, Kelly E. Lyons, and Rajesh PahwaPart II Surgical Therapy for Parkinson s Disease and Tremor4 ... Lee, and Frederick A. Lenz8 Pallidotomy for Parkinson s Disease 115Diane K. Sierens and Roy A. E. Bakay9 Bilateral Pallidotomy in Parkinson s Disease: Costs and Benefits 129Simon Parkin, ... Tipu Z. Aziz10 Subthalamotomy for Parkinson s Disease 145Steven S. Gill, Nikunj K. Patel, and Peter Heywood11 Thalamic Deep Brain Stimulation for Parkinson s Disease and Essential Tremor 153Daniel...
... and D. Galter Animal models of Parkinson s disease FEBS Journal 275 (2008) 13841391 ê 2008 The Authors Journal compilation ê 2008 FEBS 1387 MINIREVIEWParkinsons disease: genetic versus toxin-induced ... Neuroscience, Karolinska Institutet, Stockholm, SwedenIntroduction Parkinson s disease (PD) is a common neurodegenera-tive disease with a complex etiology resulting fromgenetic factors, environmental ... L-3,4-dihydroxyphenylalanine; LRRK2, leucine-rich repeat kinase 2; MAO-B, monoamine oxidase B; MPP+, 1-methyl-4-phenyl-2,3-dihydropyridium ion; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson s disease; ...
... preclinical phase of neurodegenerative disease? Insights from an animal model of Parkinsonism. Neuro-biol Dis 4, 247–253.16 Dauer W & Przedborski S (2003) Parkinson s disease: mechanisms and models. ... Parkinson s disease estimated with anunbiased stereological method. J Neurol NeurosurgPsychiatry 54, 30–33.55 Bezard E, Gross CE & Brotchie JM (2003) Presymp-tomatic compensation in Parkinson s ... tomo-graphic evidence for compensatory changes in presynap-tic dopaminergic nerve terminals in Parkinson s disease. Ann Neurol 47, 493–503.14 McCallum SE, Parameswaran N, Perez XA, Bao S, Mc-Intosh...